-
PacBio Licenses New Methylation Tech for HiFi Sequencing, Will Deliver to Revio, Vega Systems
Apr 30 | Bio-IT World | PacBio this week announced it is licensing advanced DNA methylation detection methods developed by Professor Dennis Lo and colleagues at The Chinese University of Hong Kong (CUHK) and Centre for Novostics to improve the methylation detection capabilities in HiFi chemistry. The licensed technology is designed to enhance PacBio HiFi sequencing with improved detection of DNA base modifications—including 5-hydroxymethylcytosine (5hmC) and hemimethylated 5-methylcytosine (5mC)—in native DNA. More -
Follow the Money: Cancer Platform Expansion, Wearable Device for Metabolic Health, More
Apr 29 | Bio-IT World | Caris will expand their platforms, MI Cancer Seek and Caris Assure; Biolinq will bring the first autonomous intradermal glucose sensor to market; and more. More -
Advancing Precision Medicine with Ethical AI and Standardized Data
Apr 25 | Bio-IT World | The integration of artificial intelligence (AI) into precision medicine is transforming healthcare by enabling more personalized treatment strategies. However, along with these advancements come significant ethical considerations. AI must be implemented such that it enhances, rather than replaces, the physician-patient relationship while maintaining patient autonomy, transparency, and explainability in clinical decision-making. More -
Tech Veteran Chris Dwan Challenges Life Sciences to Build Infrastructure, Businesses Strategically
Apr 23 | Bio-IT World | After years of contributing to the Bio-IT World community as a speaker, awards program judge, and leading consultant, technology expert Chris Dwan took the plenary stage at the 2025 Bio-IT World Conference & Expo, sharing wisdom gleaned from over two decades of building computing infrastructures for the New York Genome Center, Broad Institute, and Sema4 and others. More -
AI in Drug Development: Promise and Pitfalls
Apr 22 | Bio-IT World | An expert panel of technology and pharmaceutical executives convened at this month's Bio-IT World Venture, Innovation, and Partnering event to discuss the transformative potential of artificial intelligence in drug development—and the significant challenges that still lie ahead. Participants included Rory Kelleher of NVIDIA, Bill Fitzgerald from Google Cloud, Bill Mayo of Bristol-Myers Squibb, Anthony Philippakis of GV (formerly Google Ventures), and Becky Stevenson of HSBC, moderated by Jeremy Goldberg of Arsenal Capital Partners. More -
Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research
Apr 17 | Bio-IT World | At the Bio-IT World Conference & Expo earlier this month, Alex Zhavoronkov, CEO and founder of Insilico Medicine, shared the company's progress in leveraging generative AI to accelerate drug discovery, particularly focusing on aging research. Celebrating the company's 11th year, Zhavoronkov emphasized his singular mission: helping people live longer, healthier lives. More -
AI Continues to Make Strides on Therapeutics and Research Progress
Apr 16 | Bio-IT World | During the final plenary keynote of this year’s Bio-IT World Conference & Expo, we heard from Tris Dyson, Challenge Works, and Jeffrey Rothstein, Johns Hopkins University; Robert Green, Harvard Medical School; and Justin Scheer, Johnson & Johnson Innovative Medicine. They all gave presentations that highlighted artificial intelligence (AI) and machine learning’s (ML) ever-growing roles in research and healthcare, as well as the impact they have on the future of patient treatment, drug development, and more. More -
Derek Lowe on AI in Drug Discovery: Between Hype and Hope
Apr 15 | Bio-IT World | At last week’s Venture, Innovation, and Partnering Summit at the Bio-IT World Conference & Expo, Derek Lowe, Director, Chemical Biology & Therapeutics at Novartis BioMedical Research, and John Keilty, venture partner at Third Rock Ventures, sat down for a candid conversation on the pharmaceutical industry and the current state of artificial intelligence and machine learning (AI/ML) in drug discovery. More -
Large Language Model Predicts, as Well as Explains, Molecular Properties
Apr 10 | Bio-IT World | Scientists use prior knowledge to solve new problems, and a novel artificial intelligence (AI) system known as LLM4SD (Large Language Model 4 Scientific Discovery) can likewise synthesize knowledge from existing literature. But the method “goes beyond simply repeating information” by interpreting it and coming up with new hypotheses. More -
AI Struggles and Opportunities in Life Sciences and Healthcare
Apr 09 | Bio-IT World | At the opening plenary panel at last week’s Bio-IT World Conference & Expo, speakers from pharma, healthcare, and biotech took on the future of AI for pharma and healthcare. Abbie Celniker, Partner, Third Rock Ventures, moderated the conversation which included viewpoints from Per Greisen, President, BioMap; Sofia Guerra, Vice President, Bessemer Venture Partners; Subha Madhavan, Vice President and Head, AI/ML, Quantitative and Digital Sciences, Pfizer; and Sonya Makhni, MD, Medical Director, Mayo Clinic Platform. More
Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and
data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!
Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!
